A Randomized, Double-blind, Active-controlled, Parallel Group, 52-week Study to Evaluate the Effect of LCZ696 Compared to Olmesartan on Regional Aortic Stiffness in Subjects With Essential Hypertension

Trial Profile

A Randomized, Double-blind, Active-controlled, Parallel Group, 52-week Study to Evaluate the Effect of LCZ696 Compared to Olmesartan on Regional Aortic Stiffness in Subjects With Essential Hypertension

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Sacubitril/valsartan (Primary) ; Amlodipine; Olmesartan medoxomil
  • Indications Essential hypertension
  • Focus Pharmacodynamics
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 27 Sep 2017 Results published in the European Heart Journal.
    • 16 Nov 2016 Results assessing effects of LCZ696 on LV-structure and function as well as on regional and global aortic distensibility, presented at the 89th Annual Scientific Sessions of the American Heart Association
    • 13 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top